<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0028-3746</journal-id>
<journal-title><![CDATA[Neumología y cirugía de tórax]]></journal-title>
<abbrev-journal-title><![CDATA[Neumol. cir. torax]]></abbrev-journal-title>
<issn>0028-3746</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Neumología y Cirugía de Tórax; Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas; Sociedad Cubana de Neumología; Sociedad Paraguaya de Neumología; Sociedad Boliviana de Neumología.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0028-37462019000100032</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Uso de omalizumab en cinco pacientes con síndrome de sobreposición asma-EPOC (SOAE) en un Hospital Universitario de Puebla: Un estudio observacional]]></article-title>
<article-title xml:lang="en"><![CDATA[Use of omalizumab in 5 patients with Asthma-COPD overlap syndrome (ACOS) in a University Hospital of Puebla: a observational study]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Herrera-García]]></surname>
<given-names><![CDATA[José Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arellano-Montellano]]></surname>
<given-names><![CDATA[Ek I.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jaramillo-Arellano]]></surname>
<given-names><![CDATA[Luis Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Espinoza-Arellano]]></surname>
<given-names><![CDATA[Andrea]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario de Puebla  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Benemérita Universidad Autónoma del Estado de Puebla  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2019</year>
</pub-date>
<volume>78</volume>
<numero>1</numero>
<fpage>32</fpage>
<lpage>36</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0028-37462019000100032&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0028-37462019000100032&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0028-37462019000100032&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  El binomio asma/EPOC denominado SOAE (sobreposición asma/EPOC) es un subconjunto de pacientes con persistencia y limitación del flujo aéreo que presenta características clínicas tanto del asma como de la EPOC. Los estudios iniciales han demostrado que omalizumab puede ser útil en pacientes con SOAE. Ha demostrado mejorar los síntomas, reducir las exacerbaciones y la hospitalización, así como mejorar parámetros de función pulmonar y requerimiento de esteroides reducido en estos pacientes.  Objetivo:  Describir el efecto de omalizumab en cinco pacientes con diagnóstico de síndrome de sobreposición asma/EPOC (SOAE) y administración de omalizumab. Describimos la experiencia de nuestro centro y los beneficios que el tratamiento ha dado a nuestros pacientes.  Material y métodos: Se presentan 5 casos de pacientes con diagnóstico de síndrome de sobreposición asma/EPOC que tras la aplicación de omalizumab (300 mg SC cada mes) mejoraron significativamente sus síntomas y sus pruebas funcionales respiratorias, principalmente en la espirometría. Los 5 pacientes dieron su consentimiento de presentación de casos.  Resultados:  Los 5 pacientes con síndrome de sobreposición asma/EPOC que recibieron omalizumab experimentaron mejoría de los síntomas con mejoría del Cuestionario del Control del Asma de 10 a 20 y 25 puntos, así como en la espirometría. Omalizumab fue bien tolerado sin presentar complicaciones. El 100% de los pacientes presentó mejoría de los síntomas en el Cuestionario del Control del Asma, el mayor porcentaje fueron mujeres igual a como lo describe la literatura, los pacientes toleraron adecuadamente el tratamiento sin presentar efectos adversos mayores.  Conclusión:  Los casos descritos ofrecen una evidencia inicial de nuestra práctica médica sobre los beneficios del omalizumab en los pacientes con síndrome de sobreposición asma/EPOC mejorando clínicamente. Omalizumab demuestra buena tolerancia sin presentar efectos adversos. Estos beneficios permiten al paciente una mejor calidad de vida y disminuir de manera radical su morbilidad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  The binomial term overlap asthma/COPD is a subset of patients with persistence and airflow limitation that presents clinical features of both asthma and COPD. Initial studies have shown that omalizumab may be useful in patients with ACOS, it has been shown to improve symptoms, reduce exacerbations and hospitalization, as well as improve lung function parameters and reduced steroid requirement in these patients.  Objective:  To describe the effect of omalizumab in 5 patients with a diagnosis of overlying asthma/COPD syndrome (OAC) and administration of omalizumab. We describe the experience of our center and the benefits that the treatment has given to our patients.  Material and methods:  We present 5 cases of patients with a diagnosis of overlap asthma/COPD syndrome after application of omalizumab (300 mg SC each month) significantly improved their symptoms in ACT (asthma control test) and respiratory function tests, mainly in spirometry. This 5 patients gave their consent to present cases.  Results:  The 5 patients with OAC received Omalizumab have experienced improvement of symptoms in ACT (asthma control test) and improvement of 10 to 20 and 25 points. Omalizumab was well tolerated without complications. 100% of patients showed improvement in symptoms (ACT), higher percentage are women as described in the literature, patients tolerated the treatment without presenting major adverse effects.  Conclusion:  The cases described offer initial evidence of our medical practice on the benefits of omalizumab in patients with clinically improving overlying asthma/COPD syndrome. Omalizumab demonstrates good tolerance without presenting adverse effects. These benefits have allowed the patient a better quality of life and radically reduce their morbidity.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Sobreposición asma/EPOC]]></kwd>
<kwd lng="es"><![CDATA[omalizumab]]></kwd>
<kwd lng="es"><![CDATA[tratamiento]]></kwd>
<kwd lng="en"><![CDATA[Overlap asthma/COPD]]></kwd>
<kwd lng="en"><![CDATA[omalizumab]]></kwd>
<kwd lng="en"><![CDATA[treatment]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Postma]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Rabe]]></surname>
<given-names><![CDATA[KF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The asthma-COPD overlap syndrome]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>373</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1241-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sin]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[Miravitlles]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mannino]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[What is asthma-COPD overlap syndrome? Towards a consensus definition from a round Table discussion]]></article-title>
<source><![CDATA[Eur Respir J]]></source>
<year>2016</year>
<volume>48</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>664-73</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cosio]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
<name>
<surname><![CDATA[Soriano]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[López-Campos]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Definiting the asthma-COPD overlap syndrome in COPD cohort]]></article-title>
<collab>CHAIN Study</collab>
<source><![CDATA[Chest]]></source>
<year>2016</year>
<volume>149</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>45-52</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kiljander]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Helin]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Venho]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Jaakkola]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lehtimäki]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of asthma-COPD overlap syndrome among primary care asthmatics with a smoking history: a cross-sectional study]]></article-title>
<source><![CDATA[NPJ Prim care respire Med]]></source>
<year>2015</year>
<volume>25</volume>
<page-range>15047</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodrigues]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Galego]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Teixeira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vaz]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characterization of ACOS patients in a pulmonary outpatient consultation-applying the questionnaire proposed by GINA/GOLD consensus]]></article-title>
<source><![CDATA[Eur Respir J]]></source>
<year>2016</year>
<volume>48</volume>
<page-range>PA869</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yalcin]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Celik]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Yalcin]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab (anti-IgE) therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels]]></article-title>
<source><![CDATA[Immunopharmacol Immunotoxicol]]></source>
<year>2016</year>
<volume>38</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>253-6</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Busse]]></surname>
<given-names><![CDATA[WW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biologicals for asthma in patients with asthma-COPD overlap]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2017</year>
<volume>5</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>175-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maltby]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gibson]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Powell]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[McDonald]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab treatment response in a population with severe allergic asthma and overlapping COPD]]></article-title>
<source><![CDATA[Chest]]></source>
<year>2017</year>
<volume>151</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>78-89</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nayci]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Ozgur]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Tastekin]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ozge]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness of omalizumab treatment in asthma-COPD overlap syndrome]]></article-title>
<source><![CDATA[Chest 2016 Annual Meeting, 2016-10-12]]></source>
<year>2016</year>
<month>-1</month>
<day>0-</day>
<publisher-loc><![CDATA[Los Angeles, Cal ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dammert]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Jawahar]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab in patients with COPD and atopic phenotype: a case series]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>2016</year>
<volume>193</volume>
<page-range>A6246</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xia]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Cao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Xia]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Severe asthma and asthma-COPD overlap: a double agent or identical twins?]]></article-title>
<source><![CDATA[J Thorac Dis]]></source>
<year>2017</year>
<volume>9</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>4798-805</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
